Assay News and Research

RSS

Role of quantitative, multiplexed, targeted proteomics in determining variant-specific SARS-CoV-2 antibody response

Researchers developed a ‘bait and capture’ system which was further followed by a multiplexed and targeted proteomic liquid chromatography-tandem mass spectrometry analyses for the comparison of immune correlates in response to vaccination, natural infection, as well as protection against SARS-CoV-2 variants.

18 Feb 2022

Study finds antigenic profile of Omicron RBD is distinct from the prior SARS-CoV-2 variants of concern

A new study aimed to clarify whether extensive RBD mutations could affect the magnitude and immunodominance hierarchy of the host antibody response.

18 Feb 2022

Ensitrelvir, a novel SARS-CoV-2 antiviral

S-217622 reduces the viral load and help alleviate the severity of SARS-CoV-2 in infected hamsters.

17 Feb 2022

Faster transmission of SARS-CoV-2 Delta variant in households compared to Alpha

Researchers assess how fast the SARS-CoV-2 Alpha and Delta variants transmit from transmission data in a household study.

17 Feb 2022

Study explores humoral and cellular immunity conferred by second and third COVID-19 BNT162b2 vaccination in elderly

Researchers recently assessed SARS-CoV-2-specific humoral and cellular immune responses induced by the second and third doses of the BNT162b2 COVID-19 messenger ribonucleic acid-based vaccine in the elderly.

17 Feb 2022

COVID-19 vaccine-induced immunity in heart and kidney solid organ transplant recipients

The present study entailed assessments of both infected and uninfected SOTRs against the D614G-CoV2 baseline virus and eight other variants.

17 Feb 2022

ChAdOx1 vaccine found to protect Syrian hamsters against SARS-CoV-2 variants

Researchers recently evaluated the efficacy of the Oxford ChAdOx1 (AZD 1222/ AZD2816) vaccine against the Omicron, Delta, and Beta variants of SARS-CoV-2 in Syrian hamsters.

17 Feb 2022

Illumina partners with centers across France to advance a precision medicine approach for patients with late-stage cancer

Joint study will assess clinical value of comprehensive genomic profiling (CGP) on cancer therapy options in patients with advanced disease

From Illumina, Inc. 17 Feb 2022

Fortis Life Sciences Highlights First Year Success

Fortis Life Sciences, a strategic platform company providing capital, expertise, and operational resources to grow founder-led life science companies, today announced highlights from its first year of operations.

From Fortis Life Sciences 17 Feb 2022

Characterization of SARS-CoV-2 variants in unvaccinated and vaccinated U.S. military

Researchers discuss the genomic and virological characterization of SARS-CoV-2 variants among unvaccinated and vaccinated U.S military personnel.

16 Feb 2022

Detection of SARS-CoV-2 RNA by plasmonic-magnetic nanorobots

Researchers present a simple and efficient plasmonic-magnetic nanorobot for the detection of SARS-CoV-2 RNA.

16 Feb 2022

Study examines lyophilized mRNA-lipid nanoparticle vaccines with long-term stability

A new study explored the high immunogenicity and stability of lyophilized mRNA-LNP vaccines in relation to SARS-CoV-2.

16 Feb 2022

CRISPR-Cas12a assay to diagnose SARS-CoV-2 infection and detect strain-specific SNPs for variant identification

The multiplex detection approach outlined in this study has the potential to address the need to rapidly characterize the phenotype and clinical response to continually emerging SARS-CoV-2 variants as the COVID-19 pandemic continues.

16 Feb 2022

Superior immune response in vaccinated after infection with Omicron compared to unvaccinated

In a recent study posted to the medRxiv* preprint server, researchers evaluated the cross-reactivity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant-triggered neutralization and fragment crystallizable (Fc) effector functions between coronavirus disease 2019 (COVID-19)-vaccinated and unvaccinated individuals in South Africa.

16 Feb 2022

The long-term consequences of SARS-CoV-2 infection in people with HIV

In a recent study posted to the medRxiv* preprint server, an interdisciplinary team of researchers from the United States (US) analyzed a cohort of patients with human immunodeficiency virus (HIV) (PWH) recovering from coronavirus disease 2019 (COVID-19) and characterized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific immune responses in these patients.

15 Feb 2022

Assay News and Research

Role of quantitative, multiplexed, targeted proteomics in determining variant-specific SARS-CoV-2 antibody response

Study finds antigenic profile of Omicron RBD is distinct from the prior SARS-CoV-2 variants of concern

Ensitrelvir, a novel SARS-CoV-2 antiviral

Faster transmission of SARS-CoV-2 Delta variant in households compared to Alpha

Study explores humoral and cellular immunity conferred by second and third COVID-19 BNT162b2 vaccination in elderly

COVID-19 vaccine-induced immunity in heart and kidney solid organ transplant recipients

ChAdOx1 vaccine found to protect Syrian hamsters against SARS-CoV-2 variants

Illumina partners with centers across France to advance a precision medicine approach for patients with late-stage cancer

Fortis Life Sciences Highlights First Year Success

Characterization of SARS-CoV-2 variants in unvaccinated and vaccinated U.S. military

Detection of SARS-CoV-2 RNA by plasmonic-magnetic nanorobots

Study examines lyophilized mRNA-lipid nanoparticle vaccines with long-term stability

CRISPR-Cas12a assay to diagnose SARS-CoV-2 infection and detect strain-specific SNPs for variant identification

Superior immune response in vaccinated after infection with Omicron compared to unvaccinated

The long-term consequences of SARS-CoV-2 infection in people with HIV

The in vitro selection of a remdesivir-resistant SARS-CoV-2 mutation

Neutralizing antibody levels to different SARS-CoV-2 epitopes fluctuate over time

Post-vaccination titers of neutralizing antibodies revealed as a moderate predictor of vaccine-induced immunity

Antiviral activity assessment of remdesivir against 10 current and former SARS-CoV-2 variant clinical isolates

Study suggests that epigenetic memory in innate immune cells could be the key to explaining long COVID

eBook: Using iPSCs models for human disease research and drug discovery eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News